Phage-specific diverse effects of bacterial viruses on the immune system

Andrzej Górski*1,2, Ryszard Międzybrodzki1,2,3, Ewa Jończyk-Matysiak1, Maciej Żaczek1 & Jan Borysowski3

1Bacteriophage Laboratory, Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences (HIET PAS), R Weigla 12, 53-114 Wrocław, Poland
2Phage Therapy Unit, Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences (HIET PAS), R Weigla 12, 53-114 Wrocław, Poland
3Department of Clinical Immunology, Transplantation Institute, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland

*Author for correspondence: agorski@ikp.pl

“prophages are the major contributor to bacterial inter-strain immune heterogeneity manifested as variation of adaptive T- and B-cell immune responses of human lymphocytes, in vitro, to S. aureus and Streptococcus pyogenes”

First draft submitted: 25 July 2019; Accepted for publication: 22 August 2019; Published online: 19 September 2019

Keywords: cytokines • Hsp72 • immunity • immunomodulation • inflammation • phage • phage therapy • polysialic acid • transcytosis

With the increasing threat of antibiotic resistance, the interest in phage therapy (PT) as a potential solution to this crisis has rapidly grown. Recently, several reports have been published describing successful treatment of patients with life-threatening antibiotic-resistant bacterial infections, including recipients of lung allografts and treatment using genetically modified phage. Moreover, the first PT center has been opened in the USA, following the establishment of a similar unit in Belgium. These developments give credence to our decision to establish, in 2005, the first such unit operating in accordance with EMA and national regulations, which helped pave the way for future progress in PT as an option to combat the antimicrobial resistance crisis. Ample evidence derived from observational studies indicates the safety of PT. Furthermore, several clinical trials have been completed (including one performed according to all required standards of good medical practice and evidence-based medicine) and are ongoing. However, these trials are yet to provide definitive proof of the effectiveness of PT [1–4]. As the struggle to register phage as a medicinal product and to introduce it onto the market continues, parallel data have been accumulating to indicate that phage may interact not only with bacteria but also with eukaryotic cells (including cells of the immune system). Therefore, it cannot be excluded that in the future, after phage discovery, research may shift towards phage–immune system interactions, whereas, to date, work on phage interactions with their natural target (bacteria) has prevailed. Hopefully, simultaneous advancements in both research fields can bring beneficial results for human health, both in terms of combating antibiotic-resistant bacterial infections and developing novel anti-inflammatory and immunomodulatory agents with minimal toxicity and satisfactory efficacy [4,5].

We have formulated a hypothesis suggesting that phage present in the gut may migrate to blood, lymph and organs, mediating anti-inflammatory effects, and contributing to immunological tolerance and immune homeostasis – both in situ and at other sites of the body [6]. Study results have subsequently confirmed this and what is more, over 30 billion phages undergo transcytosis of the gut epithelium every day and disseminate to the blood, lymph and organs [7]. Furthermore, other cell types, including immune cells, may also take up phage through the endocytic pathway [8].

The new emerging concept of phage, as not only bacterial predators but as potential anti-inflammatory and immunomodulatory agents, needs detailed further study. One critical issue requiring clarification is phage specificity in mediating particular immune reactions. Phages are known for their high specificity toward bacteria which has
been established for decades and is applied in phage typing for classification of different bacterial strains. Are immunotrophic activities also phage specific or do phages induce similar responses, regardless of phage type?

It is believed that phage capsid proteins may primarily be responsible for phage biological properties unrelated to interactions with bacteria. These proteins vary in their immunogenicity and may elicit different antibody responses to phage, which also depends on route of administration. Further, different strains of a homologous phage recognizing a given bacterium, may express different proteins [9,10] and confer various functions to phage (e.g., persistence in circulation and antimitastatic effects). For example, a T4 phage mutant, HAP1, with a nonfunctional Hoc protein is more susceptible to the liver's Kupffer cells and is cleared more rapidly than its parental strain. Also, there are differences between HAP1 and T4 phage in their interactions with T cells and fibrinogen [11,12].

Initial studies on the effects of phage on other immune functions suggest that the effects may also differ depending on phage type. For example, purified T4 coliphage inhibits human T-cell proliferation induced via CD3-TCR complex, whereas purified staphylococcal phage exerts a co-stimulatory effect [12]. A detailed study on Staphylococcus and Pseudomonas phage revealed that although these phages induced similar responses in human peripheral blood mononuclear cells, through upregulation of gene expression of anti-inflammatory cytokines IL-1 receptor antagonist and of suppressor of cytokine signaling 3, their influence on other immune functions were restricted to the specific phage. A protolerogenic and anti-inflammatory cytokine IL-10 was induced by all tested Pseudomonas phage but not by any staphylococcal phage. On the other hand, the latter phage-induced TNFα, whereas only two out of four assayed Pseudomonas phage had similar effects. Furthermore, the TLR4 gene was downregulated solely by a Pseudomonas PMN phage, thus suggesting its anti-inflammatory action (TLR4 activation induces secretion of pro-inflammatory cytokines) [13]. Diversity of phage action on the immune system was also confirmed by recent data showing that a filamentous Pseudomonas Pf phage inhibits TNF production and phagocytosis while Escherichia coli filamentous Fol phage does not have such effects [8]. Moreover, our data indicate that both T4 coliphage and A5/80 Staphylococcus aureus phage significantly reduce the expression of human adenosivirus genes, but synthesis of viral DNA is inhibited only by T4 coliphage [14]. Additionally, there have been suggestions that temperate and lytic phage may differ in their actions on the immune system [8]. In fact, prophages are the major contributor to bacterial inter-strain immune heterogeneity manifested as variation of adaptive T- and B-cell immune responses of human lymphocytes, in vitro, to S. aureus and Streptococcus pyogenes [15].

Immunomodulatory and anti-inflammatory effects of phage may also be cell- and tissue-specific. The intranasal administration of 536_P1 (but not LM33-P1) coliphage in mice with experimental pneumonia caused an increase in lung antiviral cytokines and chemokines. Neither phage evoked changes in blood cytokine/chemokine levels, which also suggests that phage effects on the immune system may have various manifestations in different compartments of the body [16]. Phage ability to mediate tissue-specific activity is confirmed by Pincus et al. [17], where staphylococcal phage did not induce proinflammatory cytokines in human peripheral blood mononuclear cells but may have induced IFN-γ in human keratinocytes. Furthermore, we have shown that A5/80 staphylococcal phage increases the expression of IL-2 in the A549 cell line [18]; an activity that has yet to be reported for phage action on other cell types in in vitro studies. An increase of serum IL-2 levels in response to phage administration was also recently reported in mice treated with Acinetobacter baumannii phage but its cellular source is unknown [19].

As mentioned, recent data indicates that phage may be internalized by mammalian cells and large numbers transcytose across gut epithelial cells while immune cells also internalize phages, especially dendritic cells (DCs), monocytes and B cells [7,8]. Recently, we described a marked phage-dependent stimulation of Hsp72 gene [18]. This induction of a known cellular chaperone may be a mechanism for protecting cells undergoing transcytosis from potential injury by intracellular phage. What is more, Hsp72 is known to decrease T-cell proliferation and cytokine secretion regardless of stimuli used and inhibits DC ability to stimulate allogeneic T cells. This may suggest that Hsp72 could be used as an immunomodulator [20]. It has also been shown to suppress experimental arthritis in rats [21]. We have reported that phage can inhibit the development of collagen-induced arthritis in mice, an experimental model of rheumatoid arthritis [22]. Interestingly, Hsp72 was also shown to suppress arthritis in this model [23]. It may well be that phage-dependent induction of Hsp72 is at least partly responsible for inhibition of aberrant immune reactions (including autoimmunity and hyperinflammation) caused by phage [24].

Phage interactions with immune cells may be dependent on specific phage receptors enabling those interactions. Data are scarce at present on the nature of such receptors. Pruzzo et al. [25] suggested that coliphages T3 and T7 could adhere to epithelial cells using their receptors for Klebsiella pneumoniae. Our hypothesis pointed to a Lys-Gly-Asp (KGD) sequence present in one of the capsid proteins of T4 phage as a potential ligand for cell integrin receptors [24]. Lehti et al. showed that E. coli phage may recognize and bind neuroblastoma cells displaying polysialic
acid on their surface [26]. If indeed polysialic acid is a ligand for receptors of some phages it could enable those phages to bind to immune cells as the presence of polysialic acid has also been demonstrated on human DCs, NK cells and a subpopulation of T cells [27,28]. Thus, it is likely that various phages may use different cellular ligands to attach to and transcytose target cells including those of the immune system. Notably, even a single amino acid substitution in a phage capsid protein may cause > 1000-fold enhancement of phage survival in mouse circulation, which probably reflects modified interactions between phage and phagocytes (and perhaps other cells endocytosing phage) [29].

Phage not only target specific bacteria but – at least to some extent – can also cause phage-specific immune responses. These findings open a new exciting field for further research on the significance of such responses in health and disease. Furthermore, these data suggest that a specific phage could be optimally selected for use in PT from different phage strains recognizing a given bacterium, considering both its anti-bacterial activity and the type of immune response it may evoke. This is important in patients with immunodeficiencies, autoimmunity, allograft recipients, etc. who – pending the nature of their disease – may require immunostimulation or immunosuppression. Evidently, further research in this field may pave the way for the use of specific phage in immunomodulation.

Financial & competing interests disclosure
This work has been partially supported by grant number DEC-2013/11/B/NZ1/02107 from the National Science Center. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Open access
This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

References
1. Crunkhorn S. Phage therapy for Mycobacterium abscessus. Nat. Rev. Drug Discov. 18(7), 500 (2019).
2. Aslam S, Courtwright AM, Koval C et al. Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am. J. Transplant. doi:10.1111/ajt.15503 (2019) (Epub ahead of print).
3. Dedrick RM, Guerrero-Bustamante CA, Garlena RA et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25(5), 730–733 (2019).
4. Górski A, Międzybrodzki R, Węgrzyn G et al. Phage therapy: current status and perspectives. Med. Res. Rev. doi:10.1002/med.21593 (2019) (Epub ahead of print).
5. Górski A, Jończyk-Matysiak E, Międzybrodzki R et al. Phage therapy: beyond antibacterial action. Front. Med. 5, 146 (2018).
6. Górski A, Ważna E, Weber-Dąbrowska B et al. Bacteriophage translocation. FEMS Immunol. Med. Microbiol. 46, 313–319 (2006).
7. Nguyen S, Baker K, Padman BS et al. Bacteriophage transcytosis provides a mechanism to cross epithelial cell layers. MBio 8(6), e01874-17 (2017).
8. Sweere JM, Van Belleghem JD, Ishak H et al. Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. Science 363(6434), pii:eaat9691 (2019). (Epub ahead of print).
9. Dąbrowska K, Miernikiewicz P, Piotrowicz A et al. Immunogenicity studies of proteins forming the T4 phage head surface. J. Viral. 88(11), 12551–12557 (2014).
10. Zaczek M, Łusiak-Szelachowska M, Jończyk-Matsyia E et al. Antibody production in response to staphylococcal MS-1 phage cocktail in patients undergoing phage therapy. Front. Microbiol. 24(7), 1681 (2016).
11. Dąbrowska K, Zembala M, Boratyński J et al. Hoc protein regulates the biological effects of T4 phage in mammals. Arch. Microbiol. 187, 489–498 (2007).
12. Górski A, Międzybrodzki R, Borysowski J et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv. Virus Res. 83, 41–47 (2012).
13. Van Belleghem JD, Clement F, Merabishvili M et al. Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages. Sci. Rep. 7(1), 8004 (2017).
14. Przybylski M, Dzieciatkowski T, Borysowski J et al. Inhibitory effects of bacteriophage preparations on adenoviral replication. Intervironology 62(1), 37–44 (2019).
15. Sela U, Euler CW, Correa da Rosa J et al. Strains of bacterial species induce a greatly varied acute adaptive immune response: the contribution of the accessory genome. PLoS Pathog. 14(1), e1006726 (2018).
16. Dufour N, Delattre R, Chevallereau A et al. Phage therapy of pneumonia is not associated with an over stimulation of the inflammatory response compared to antibiotic treatment in mice. *Antimicrob. Agents Chemother.* doi:10.1128/AAC.00379-19 (2019) (Epub ahead of print).

17. Pincus NB, Reckhow JD, Saleem D et al. Strain specific phage treatment for *Staphylococcus aureus* infection is influenced by host immunity and site of infection. *PLoS ONE* 10(4), e0124280 (2015).

18. Borysowski J, Przybylski M, Międzybrodzki R et al. The effects of bacteriophages on the expression of genes involved in antimicrobial immunity. *Adv. Hyg. Exp. Med.* 73, 414–420 (2019).

19. Cha K, Oh HK, Jang JY et al. Characterization of two novel bacteriophages infecting multidrug-resistant (MDR) *Acinetobacter baumannii* and evaluation of their therapeutic efficacy in vivo. *Front. Microbiol.* 9, 696 (2018).

20. Stocki P, Wang XN, Dickinson AM. Inducible heat shock protein 70 reduces T cell responses and stimulatory capacity of monocyte-derived dendritic cells. *J. Biol. Chem.* 287(15), 12387–12394 (2012).

21. Spierings J, Van Eden W. Heat shock proteins and their immunomodulatory role in inflammatory arthritis. *Rheumatology (Oxford)* 56(2), 198–208 (2017).

22. Międzybrodzki R, Borysowski J, Kłak M et al. In vivo studies on the influence of bacteriophage preparations on the autoimmune inflammatory process. *Biomed. Res. Int.* 2017, 3612015 (2017).

23. Luo X, Zuo X, Mo X et al. Treatment with recombinant *Hsp72* suppresses collagen-induced arthritis in mice. *Inflammation* 34(5), 432–439 (2011).

24. Górski A, Dąbrowska K, Międzybrodzki R et al. Phages and immunomodulation. *Future Microbiol.* 12, 905–914 (2017).

25. Pruzzo C, Debbia EA, Satta G. Identification of the major adherence ligand of *Klebsiella pneumoniae* in the receptor for coliphage T7 and alteration of *Klebsiella* adherence properties by lysogenic conversion. *Infect. Immun.* 30(2), 562–571 (1980).

26. Lehti TA, Pajunen MI, Skog MS et al. Internalization of a polysialic acid-binding *Escherichia coli* bacteriophage into eukaryotic neuroblastoma cells. *Net. Commun.* 8(1), 1915 (2017).

27. Drake PM, Nathan JK, Stock CM et al. Polysialic acid, a glycan with highly restricted expression, is found on human and murine leukocytes and modulates immune responses. *J. Immunol.* 181(10), 6850–6858 (2008).

28. Villanueva-Cabello TM, Gutierrez-Valenzuela LD, Lopez-Guerrero DV et al. Polysialic acid is expressed in human naïve CD4+ T cells and is involved in modulating activation. *Glycobiology* 29(7), 557–564 (2019).

29. Vitiello CL, Merril CR, Adhya S. An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. *Virus Res.* 114(1–2), 101–103 (2005).